Related Experiment Video
Updated: May 15, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose
Abstract:
We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, naïve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Dosage Regimens: Partial Pharmacokinetic Parameters
Bioavailability: Influencing Factors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Retrovirus Life Cycles
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

